more modulatory roles, fine-tuning the balance between neuronal excitation and inhibition.
Positive AMPA receptor modulators strengthen excitatory transmission, enhance synaptic plasticity, and preclinical and preliminary clinical research suggested efficacy as cognition enhancers (Lynch, 2006; O'Neill and Dix, 2007 ). The first potentiator tested in large clinical trials was CX516 (Cortex Pharmaceuticals), which did not show efficacy in a variety of pathologies (eg Berry- Kravis et al, 2006) . In contrast, a second-generation ampakine, CX717, normalized behaviors associated with attention deficit hyperactivity disorder (ADHD). Further testing of CX717 for ADHD was not approved by the US Food and Drug Administration due to toxicological concerns, although approval was granted to continue trials of CX717 in Alzheimer's disease. The outcome of this project is uncertain, however, given that a chemically distinct potentiator, LY415395 (Eli Lilly), failed to improve cognitive performance in an Alzheimer's disease trial (Chappell et al, 2007) . Recently, compelling preclinical data prompted initiation of two Phase II trials in Germany to determine if CX717 reverses or prevents respiratory depression during opiate analgesia. These appear to be the only ongoing studies of efficacy for positive AMPA receptor modulators in humans, as clinical studies for similar molecules have been suspended (ScheringPlough) or the results remain undisclosed (Servier, GlaxoSmithKline).
Noncompetitive inhibitors of AMPA receptors, such as talampanel (Teva Pharmaceuticals) and perampanel (Eisai Medical Research), reduce overexcitation and potentially slow neurodegeneration. These drugs were efficacious as adjunct therapies for refractory partial complex seizures (Howes and Bell, 2007) ; perampanel also alleviated diabetic and postherpetic neuropathic pain and will be further tested for these indications. Results released from an in-progress study suggested that talampanel decreased mortality from glioblastoma, and an examination of its efficacy in amyotrophic lateral sclerosis is planned. Advances in the field of genomics offer new diagnostic and screening potential for complex genetic diseases like addiction. The ability to simultaneously measure the level of all possible transcripts (mRNAs) provides an unbiased view of potential biomarkers. The importance of understanding gene expression changes in alcohol and drug dependence can be appreciated by the impact of expression profiling in other diseases, most notably cancer, where studies have led to improved pharmacotherapies and to a molecular classification of disease. Gene expression profiling is only beginning to be applied to psychiatric illnesses and may also provide an accurate means to diagnose these conditions. Human brain gene expression studies of alcoholics and cocaine abusers suggest that specific patterns of gene expression may underlie addiction-related phenotypes and provides evidence that a molecular classification of alcoholism may be feasible in the future (Liu et al, 2006; Mash et al, 2007) . However, in order for expression profiling to be useful in the clinical screening of dependence and consumption, the tissues or cells under investigation need to be readily accessible. A wide variety of screening tests are available that relies upon peripheral blood samples for assaying biological markers. For example, blood tests allow early detection, and in some cases prevention, of conditions such as prostate cancer, diabetes, thyroid dysfunction, and heart disease. Blood samples offer advantages over procedures such as tissue biopsy as they are fast, noninvasive, and can be repeated many times on the same individual. Blood biomarkers also offer the potential to predict disease before any detrimental symptoms are manifested. Genomic profiling of peripheral blood samples could be of great value in identifying biomarkers for complex diseases including addiction. This idea is supported by studies utilizing white blood cells to identify discrete patterns of expression associated with modeled complex disease states in animals (Tang et al, 2001 ). In addition, patterns of gene expression have been identified from blood samples obtained from a large number of healthy individuals, revealing surprising consistency in expression of genes associated with age, gender, and blood composition (Tang et al, 2001) . Thus, it's feasible that nucleated blood cells of alcohol-dependent individuals could show changes in gene expression that will provide a 'signature' of the disease.
Discovery of reliable blood-based molecular markers of alcohol dependence and use would mark a milestone for addiction research and offer a great benefit for predicting the disease even without knowing the role of the markers in the disease process. Once biomarkers are discovered, the opportunity for early detection and intervention as well as personalized therapeutics should lead to new treatments for the disease. One approach to circumvent this high attrition rate would be to use in vivo models directly in the discovery phase to identify candidates with desired biological profiles while simultaneously eliminating those compounds with poor absorption, distribution, metabolism, and elimination (ADME)/ pharmacokinetic (PK) properties.
It is clearly unrealistic to use discovery in vivo models to screen the large collections of hundreds of thousands of the individual compounds currently available. A potential solution that shows promise is the use of mixture-based combinatorial libraries directly for in vivo testing. This offers a unique opportunity to carry out successful preliminary studies in which tens to hundreds of thousands of compounds would be screened directly in translational in vivo assays. This has been accomplished in early studies carried out in rats and dogs to monitor blood pressure and heart rate (Houghten, 1994) using 400 separate mixtures each of 132 000 hexapeptides. Immunological modulation by large mixtures has also been accomplished (Shukaliak Quandt et al, 2004) . Recent studies have involved research into pain therapeutics utilizing in vivo
